Fifty adults is a small number to anchor a treatment hypothesis on, but the signal emerging from CU Anschutz’s eight-week randomized, double-blind, placebo-controlled trial of oral semaglutide for Alcohol Use Disorder is coherent enough that the addiction medicine field is unlikely to ignore it. Published today in The American Journal of Psychiatry, the study found that participants receiving oral semaglutide showed fewer heavy drinking days, reduced alcohol consumption per drinking occasion, lower day-to-day cravings, fewer alcohol-related problems, and improved overall drinking risk level compared to placebo. A secondary finding, reduced cannabis use days, was not a primary endpoint but adds a layer of interest around GLP-1 receptor agonism and reward-pathway biology more broadly.
The formulation choice here is deliberate and clinically meaningful. Injectable semaglutide has already been evaluated in AUD populations, including a 26-week, 108-participant randomized trial examining once-weekly subcutaneous dosing in patients with comorbid obesity. The CU Anschutz team hypothesized that oral delivery would be more acceptable to people with AUD, a population with high rates of injection aversion, medication discontinuation, and competing comorbidities. Adherence and completion rates in this trial were high, which matters for feasibility arguments when designing the larger studies that must follow. Eight weeks is not long enough to draw conclusions about durability, relapse prevention, or liver outcomes, but it is long enough to establish that real-world drinking behavior shifted in a clinically relevant direction.
The regulatory backdrop gives these findings added weight. FDA-approved pharmacotherapies for AUD, including disulfiram, naltrexone, and acamprosate, have been on the market for years, and no new molecular entity has cleared that bar since 2006. That stagnation is not for lack of unmet need. A significant share of people with moderate-to-severe AUD do not respond to existing agents, and the condition carries substantial burden across physical health, mental health, and social functioning. Oral semaglutide, if it holds up in larger trials, would not need to be a cure to matter: even a durable reduction in heavy drinking days translates into measurable harm reduction at a population scale.
CU Anschutz and partner institutions are planning larger trials. The single variable worth tracking is whether those expanded studies are designed around abstinence endpoints or reduction endpoints, because that choice will define both the regulatory strategy and the patient population that ultimately benefits.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
